Study of Clinical Outcomes of More Frequent Hemodialysis

Satellite Healthcare2 sites in 1 country46 target enrollmentJanuary 2005

ConditionsEnd Stage Renal Disease Chronic Kidney Disease

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: End Stage Renal Disease
Sponsor: Satellite Healthcare
Enrollment: 46
Locations: 2
Primary Endpoint: Hospitalization days per year
Status: Completed
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The study compares the benefits of short daily hemodialysis six days a week, nocturnal (night time) hemodialysis six days a week, every other day and every other night hemodialysis to traditional three days a week hemodialysis.The hypothesis is that increasing hemodialysis treatment time and/or frequency will improve outcomes.

Registry

clinicaltrials.gov

Start Date

January 2005

End Date

August 7, 2012

Last Updated

7 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Satellite Healthcare

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Stable vascular access, i.e., lack of needling difficulties and stable flow rates. Accesses will include fistulae, grafts, catheters and ports.
•18 years of age.
•History of compliance with a dialysis treatment schedule, or if a new patient, express a willingness to be compliant with a treatment schedule.
•Plan to continue care and follow-up at the investigational site.
•Able to sign the informed consent and other relevant documents.

Exclusion Criteria

•History of poor compliance with thrice (or twice) weekly dialysis schedules as manifested by more than three unexplained missed treatments in the past six (6) months.
•Pregnancy.
•Intravenous drug abuser.
•Expects to receive a transplant or transfer to another facility within six months of entering the study.

Outcomes

Primary Outcomes

Hospitalization days per year

Time Frame: Ongoing

Secondary Outcomes

Nutritional Status measured by Subjective Global Assessment(Ongoing)
Control of hypertension, as measured by number of antihypertensive tablets taken per day(Ongoing)
Control of hyperphosphatemia, as measured by number of phosphate binder tablets taken per day(Ongoing)
Anemia, measured by erythropoetin dose(Ongoing)